Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

January 23, 2026 03:34:45 am

Source: SeekingAlpha

2026-01-23 03:34:45 ET

Overview

It has been an eventful start to the year for Alpha Tau Medical (DRTS), which I first wrote about back in October as a unique technology/mechanism and a story set to inflect over 2026 and beyond. The stock is up ~70% since my initiation and ~35% YTD (after two rather aggressive days of retracement). Some of the events/headlines driving the move over the last couple of months include:

Visibility : Participation in investor conferences in December (Piper Sandler and Sidoti) and then the JPM Healthcare Conference last week. Alpha Tau was and still largely is an underknown name to biotech investors—these conference appearances have begun to help change that. Average daily volume has increased from sub-100k shares in the summer/fall to ~400k over the past month or so.
December 2nd : Clearance from the FDA to begin a trial in prostate cancer, marking its fifth active indication in the US ( link ).
December 9th : Treatment of its first GBM patient ( link ).
January 5th : The announcement that the FDA had agreed to the use of a more flexible, modular (essentially rolling ) submission process for Alpha DaRT in cutaneous squamous cell carcinoma (cSCC), in which they expect to report pivotal data in 2H26. ( Link ). I think investors have come to appreciate that Alpha Tau receives unique treatment from the FDA, including its standing quarterly meeting with the agency to discuss and update on its various programs.
January 6th : Announced the final results from its first-in-human pancreatic cancer trial that was conducted in Montreal ( link ). As I discussed in my initiation, this study was a bit of a hodgepodge of different treatment lines, disease stages, etc., but demonstrates impressive activity in severely undertreated pancreatic cancer, especially considering the trial used only incomplete tumor coverage (tumors were only partially covered with DaRTs). Most of this data had already been reported, though there were some interesting new biomarker data.